Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt N/A
ABT's Cash-to-Debt is ranked lower than
81% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. ABT: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
ABT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: N/A
Current: N/A
Equity-to-Asset 0.44
ABT's Equity-to-Asset is ranked lower than
75% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABT: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
ABT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.47 Max: 0.59
Current: 0.44
0.37
0.59
Interest Coverage 3.05
ABT's Interest Coverage is ranked lower than
85% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. ABT: 3.05 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 3.05  Med: 11.51 Max: 17.59
Current: 3.05
3.05
17.59
Piotroski F-Score: 5
Altman Z-Score: 2.49
Beneish M-Score: -2.36
WACC vs ROIC
10.16%
9.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.77
ABT's Operating Margin % is ranked higher than
71% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. ABT: 8.77 )
Ranked among companies with meaningful Operating Margin % only.
ABT' s Operating Margin % Range Over the Past 10 Years
Min: 8.77  Med: 16.29 Max: 20.28
Current: 8.77
8.77
20.28
Net Margin % 4.96
ABT's Net Margin % is ranked higher than
68% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. ABT: 4.96 )
Ranked among companies with meaningful Net Margin % only.
ABT' s Net Margin % Range Over the Past 10 Years
Min: 4.96  Med: 13.54 Max: 21.68
Current: 4.96
4.96
21.68
ROE % 5.13
ABT's ROE % is ranked higher than
60% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. ABT: 5.13 )
Ranked among companies with meaningful ROE % only.
ABT' s ROE % Range Over the Past 10 Years
Min: 5.13  Med: 20.58 Max: 28.49
Current: 5.13
5.13
28.49
ROA % 2.41
ABT's ROA % is ranked higher than
60% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. ABT: 2.41 )
Ranked among companies with meaningful ROA % only.
ABT' s ROA % Range Over the Past 10 Years
Min: 2.41  Med: 8.81 Max: 12.12
Current: 2.41
2.41
12.12
ROC (Joel Greenblatt) % 26.06
ABT's ROC (Joel Greenblatt) % is ranked higher than
74% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. ABT: 26.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.28  Med: 44.88 Max: 65.75
Current: 26.06
22.28
65.75
3-Year Revenue Growth Rate 0.40
ABT's 3-Year Revenue Growth Rate is ranked lower than
54% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ABT: 0.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.8  Med: 9.7 Max: 15.2
Current: 0.4
-18.8
15.2
3-Year EBITDA Growth Rate -8.30
ABT's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. ABT: -8.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21.2  Med: 8.7 Max: 31.6
Current: -8.3
-21.2
31.6
3-Year EPS without NRI Growth Rate -17.40
ABT's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABT: -17.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.6  Med: 11.9 Max: 125.5
Current: -17.4
-65.6
125.5
GuruFocus has detected 10 Warning Signs with Abbott Laboratories $ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 30-Y Financials

Financials (Next Earnings Date: 2017-10-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ABT Guru Trades in Q3 2016

Steven Cohen 606,700 sh (New)
Jim Simons 657,300 sh (New)
Stanley Druckenmiller 1,068,000 sh (+177.11%)
Mairs and Power 1,089,562 sh (+168.05%)
Jeremy Grantham 4,510,348 sh (+3.80%)
Ken Fisher 12,435 sh (+0.39%)
Mario Gabelli 13,695 sh (+0.07%)
Vanguard Health Care Fund 10,508,900 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
Steven Cohen 200,000 sh (unchged)
David Carlson 420,000 sh (unchged)
Joel Greenblatt Sold Out
Spiros Segalas Sold Out
Jeff Auxier 78,622 sh (-0.06%)
John Buckingham 133,239 sh (-0.25%)
Diamond Hill Capital 11,875,781 sh (-0.78%)
Murray Stahl 22,628 sh (-1.52%)
Manning & Napier Advisors, Inc 149,363 sh (-1.88%)
PRIMECAP Management 15,720,699 sh (-4.60%)
Richard Pzena 5,017,660 sh (-5.81%)
Pioneer Investments 908,362 sh (-7.21%)
George Soros 259,181 sh (-21.26%)
Paul Tudor Jones 16,600 sh (-36.88%)
Ray Dalio 62,000 sh (-40.44%)
First Eagle Investment 1,271,914 sh (-57.24%)
» More
Q4 2016

ABT Guru Trades in Q4 2016

Keeley Asset Management Corp 35,610 sh (New)
Joel Greenblatt 1,010,598 sh (New)
Jim Simons 2,980,400 sh (+353.43%)
Ray Dalio 80,200 sh (+29.35%)
Mairs and Power 1,333,036 sh (+22.35%)
Ken Fisher 14,794 sh (+18.97%)
Diamond Hill Capital 12,488,011 sh (+5.16%)
Manning & Napier Advisors, Inc 154,272 sh (+3.29%)
Vanguard Health Care Fund 10,758,900 sh (+2.38%)
Paul Tudor Jones 16,800 sh (+1.20%)
Richard Pzena 5,049,688 sh (+0.64%)
Jeff Auxier 78,664 sh (+0.05%)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
David Carlson 420,000 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen Sold Out
Stanley Druckenmiller Sold Out
Pioneer Investments Sold Out
John Buckingham 132,868 sh (-0.28%)
Murray Stahl 22,528 sh (-0.44%)
Mario Gabelli 13,625 sh (-0.51%)
Jeremy Grantham 4,484,944 sh (-0.56%)
PRIMECAP Management 14,859,619 sh (-5.48%)
George Soros 229,181 sh (-11.57%)
» More
Q1 2017

ABT Guru Trades in Q1 2017

Mairs and Power 4,270,907 sh (+220.39%)
Mario Gabelli 43,633 sh (+220.24%)
Vanguard Health Care Fund 17,608,199 sh (+63.66%)
Jeff Auxier 108,013 sh (+37.31%)
Manning & Napier Advisors, Inc 194,870 sh (+26.32%)
Ken Fisher 16,656 sh (+12.59%)
Jeremy Grantham 5,008,798 sh (+11.68%)
Murray Stahl 23,728 sh (+5.33%)
Jim Simons 3,124,266 sh (+4.83%)
John Buckingham 133,698 sh (+0.62%)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
David Carlson 420,000 sh (unchged)
George Soros Sold Out
Ray Dalio Sold Out
PRIMECAP Management 14,730,964 sh (-0.87%)
Diamond Hill Capital 12,291,387 sh (-1.57%)
Richard Pzena 2,922,096 sh (-42.13%)
Paul Tudor Jones 8,900 sh (-47.02%)
Joel Greenblatt 399,925 sh (-60.43%)
» More
Q2 2017

ABT Guru Trades in Q2 2017

Ken Fisher 343,410 sh (+1961.78%)
Manning & Napier Advisors, Inc Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, NAS:ALGN, NYSE:VAR, NYSE:TFX, NAS:ABMD, NAS:MASI, NAS:IART, NAS:NUVA, NYSE:GMED, NYSE:PEN, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NAS:CNMD, NYSE:ITGR » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, 0Q15.UK,
Headquarter Location:USA
Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.

Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Guru Investment Theses on Abbott Laboratories

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Abbott Laboratories

Abbott Laboratories Releases 2nd-Quarter Figures The medical devices segment drove revenue growth
Abbott Laboratories (NYSE:ABT) released its second-quarter 2017 results on July 20. Read more...
What's Behind Thursday's Morning Movements? 3 stocks are moving on the back of earnings reports
Stocks traded slightly in the green ahead of earnings from Abbott Laboratories (NYSE:ABT), American Express Co. (NYSE:AXP), Bank of New York Mellon Corp. (NYSE:BK), eBay Inc. (NASDAQ:EBAY), Intuitive Surgical Inc. (NASDAQ:ISRG), Microsoft Corp. (NASDAQ:MSFT), Philip Morris International Inc. (NYSE:PM), Sherwin-Williams Co. (NYSE:SHW), T-Mobile US Inc. (NASDAQ:TMUS), Union Pacific Corp. (NYSE:UNP), Qualcomm Inc. (NASDAQ:QCOM) and Visa Inc. (NYSE:V). Read more...
Abbott Labs Places Tender Offer for Alere's Preferred Stock The company will pay $402 per share
Abbott Laboratories (NYSE:ABT) announced July 17 it is offering to buy all of Alere Inc.'s (NYSE:ALR) preferred stockRead more...
Abbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies
Shareholders Approve Alere, Abbott Merger The deal is valued at $5.3 billion
Alere Inc. (NYSE:ALR) announced July 7 that its shareholders, who hold approximately 72.5% of the company’s total volume of outstanding shares, approved the amended merger deal with Abbott Laboratories (NYSE:ABT). Read more...
Guggenheim Starts Covering Abbott Laboratories Firm began with a buy rating and set a price target of $58 per share
Guggenheim initiated coverage with a buy rating on shares of Abbott Laboratories (NYSE:ABT) and set a price target of $58 per share, as reported by Benzinga. Read more...
Abbott Hosts Conference Call for Second-Quarter Earnings
Abbott Labs Declares Quarterly Dividend Global health care company will pay its shareholders 26.5 cents per share
Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share June 9. Read more...
Abbott Declares 374th Consecutive Quarterly Dividend

Ratios

vs
industry
vs
history
PE Ratio 70.47
ABT's PE Ratio is ranked lower than
69% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. ABT: 70.47 )
Ranked among companies with meaningful PE Ratio only.
ABT' s PE Ratio Range Over the Past 10 Years
Min: 5.78  Med: 11.36 Max: 70.99
Current: 70.47
5.78
70.99
Forward PE Ratio 20.41
ABT's Forward PE Ratio is ranked higher than
78% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. ABT: 20.41 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 78.16
ABT's PE Ratio without NRI is ranked lower than
70% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. ABT: 78.16 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 25.08 Max: 250.57
Current: 78.16
5.93
250.57
Price-to-Owner-Earnings 42.72
ABT's Price-to-Owner-Earnings is ranked lower than
58% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. ABT: 42.72 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.45  Med: 12.61 Max: 631.91
Current: 42.72
4.45
631.91
PB Ratio 2.77
ABT's PB Ratio is ranked higher than
55% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ABT: 2.77 )
Ranked among companies with meaningful PB Ratio only.
ABT' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.32 Max: 3.34
Current: 2.77
1.39
3.34
PS Ratio 3.47
ABT's PS Ratio is ranked lower than
51% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. ABT: 3.47 )
Ranked among companies with meaningful PS Ratio only.
ABT' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.61 Max: 3.78
Current: 3.47
0.96
3.78
Price-to-Free-Cash-Flow 27.67
ABT's Price-to-Free-Cash-Flow is ranked higher than
56% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. ABT: 27.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 10.12 Max: 40.05
Current: 27.67
4.39
40.05
Price-to-Operating-Cash-Flow 19.57
ABT's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. ABT: 19.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.82  Med: 7.41 Max: 23.85
Current: 19.57
3.82
23.85
EV-to-EBIT 43.37
ABT's EV-to-EBIT is ranked lower than
68% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. ABT: 43.37 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.4  Med: 10.3 Max: 43.63
Current: 43.37
5.4
43.63
EV-to-EBITDA 24.43
ABT's EV-to-EBITDA is ranked lower than
60% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. ABT: 24.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 7.6 Max: 24.58
Current: 24.43
4.3
24.58
Shiller PE Ratio 17.89
ABT's Shiller PE Ratio is ranked higher than
94% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 49.44 vs. ABT: 17.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.96  Med: 12.94 Max: 18.16
Current: 17.89
8.96
18.16
Current Ratio 2.91
ABT's Current Ratio is ranked higher than
55% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. ABT: 2.91 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.34 Max: 4.02
Current: 2.91
0.75
4.02
Quick Ratio 2.31
ABT's Quick Ratio is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ABT: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.99 Max: 3.65
Current: 2.31
0.55
3.65
Days Inventory 98.83
ABT's Days Inventory is ranked higher than
61% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. ABT: 98.83 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 76.02  Med: 88.71 Max: 117.89
Current: 98.83
76.02
117.89
Days Sales Outstanding 69.73
ABT's Days Sales Outstanding is ranked lower than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. ABT: 69.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.85  Med: 68.62 Max: 77.62
Current: 69.73
56.85
77.62
Days Payable 49.99
ABT's Days Payable is ranked higher than
50% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. ABT: 49.99 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 39.77 Max: 49.99
Current: 49.99
35.38
49.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.11
ABT's Dividend Yield % is ranked higher than
83% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. ABT: 2.11 )
Ranked among companies with meaningful Dividend Yield % only.
ABT' s Dividend Yield % Range Over the Past 10 Years
Min: 1.41  Med: 4.84 Max: 7.9
Current: 2.11
1.41
7.9
Dividend Payout Ratio 1.17
ABT's Dividend Payout Ratio is ranked higher than
59% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. ABT: 1.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.57 Max: 13.4
Current: 1.17
0.42
13.4
3-Year Dividend Growth Rate 22.90
ABT's 3-Year Dividend Growth Rate is ranked higher than
79% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 11.10 vs. ABT: 22.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 11.5 Max: 22.9
Current: 22.9
-31.2
22.9
Forward Dividend Yield % 2.10
ABT's Forward Dividend Yield % is ranked higher than
82% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 1.51 vs. ABT: 2.10 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.07
ABT's 5-Year Yield-on-Cost % is ranked lower than
62% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABT: 1.07 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 2.47 Max: 4.03
Current: 1.07
0.72
4.03
3-Year Average Share Buyback Ratio 1.60
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ABT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.5 Max: 2.2
Current: 1.6
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.43
ABT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ABT: 1.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.85 Max: 1.81
Current: 1.43
0.36
1.81
Price-to-Median-PS-Value 2.15
ABT's Price-to-Median-PS-Value is ranked lower than
82% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ABT: 2.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53  Med: 0.96 Max: 2.26
Current: 2.15
0.53
2.26
Earnings Yield (Greenblatt) % 2.31
ABT's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ABT: 2.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.29  Med: 9.7 Max: 18.5
Current: 2.31
2.29
18.5
Forward Rate of Return (Yacktman) % -12.88
ABT's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. ABT: -12.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.6  Med: 12.05 Max: 32.3
Current: -12.88
-13.6
32.3

More Statistics

Revenue (TTM) (Mil) $23,607.00
EPS (TTM) $ 0.71
Beta1.54
Short Percentage of Float1.00%
52-Week Range $37.38 - 51.13
Shares Outstanding (Mil)1,735.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 26,677 28,105 29,381
EPS ($) 2.46 2.76 3.09
EPS without NRI ($) 2.46 2.76 3.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.81%
Dividends per Share ($) 1.09 1.15 1.22
» More Articles for ABT

Headlines

Articles On GuruFocus.com
What's Behind Thursday's Morning Movements? Jul 20 2017 
Abbott Laboratories Releases 2nd-Quarter Figures Jul 20 2017 
Abbott Labs Places Tender Offer for Alere's Preferred Stock Jul 18 2017 
Abbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Pref Jul 17 2017 
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies Jul 13 2017 
Shareholders Approve Alere, Abbott Merger Jul 10 2017 
Guggenheim Starts Covering Abbott Laboratories Jun 29 2017 
Abbott Hosts Conference Call for Second-Quarter Earnings Jun 21 2017 
AstraZeneca: 4% Dividend Yield and a Pipeline to Emerging Market Growth Jun 15 2017 
Steven Cohen Bullish on Health Care Sector Jun 14 2017 

More From Other Websites
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger Jul 26 2017
Analysts Raise Recommendations on Abbott Stock after 2Q17 Jul 26 2017
Abbott Laboratories’ Updated Guidance for 2017 Jul 26 2017
What Were Abbott’s Key Growth Drivers for 2Q17? Jul 25 2017
Abbott Laboratories’ 2Q17 Results: Which Segment Fared Best? Jul 25 2017
Strong 2Q17 Results Trigger Rise in Abbott Stock Jul 25 2017
Abbott deal will cost Alere three business units — and untold employees Jul 24 2017
Abiomed Expects to Expand Its Presence in This Space Jul 24 2017
Abiomed Impella Quality Program Will Boost Demand in Fiscal 2018 Jul 21 2017
Behind the Major Drivers of JNJ’s Medical Device Growth Jul 21 2017
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018 Jul 21 2017
Company News for July 21, 2017 Jul 21 2017
Today's Research Reports on Stocks to Watch: Abbott Laboratories and Pfizer Inc. Jul 21 2017
Abbott tops Street 2Q forecasts Jul 20 2017
LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards? Jul 20 2017
Abiomed in 2017: The Analysts’ View Jul 20 2017
Markets Right Now: US struggle to a mixed finish Jul 20 2017
Abbott Zeros In On A 2-Year High After Topping Q2 Sales, Profits Jul 20 2017
US STOCKS-S&P, Dow flat as retailers weigh; Nasdaq edges higher Jul 20 2017
Abbott profit forecast gets a lift from St. Jude integration Jul 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}